Clinical trials: Dysthyroid Orbitopathy
Thyroid Eye Disease
A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked phase II study evaluating the efficacy and safety of IBI311 in subjects with inactive or active thyroid eye disease.
- Trial name
- NCT06525506
- Testing
- IBI311 (20 mg), IBI311 (3-20 mg), IBI311 (10 mg)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Thyroid Associated Ophthalmopathies
MHB018A Treatment in Patients With Active Thyroid Eye Disease
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants…
- Trial name
- NCT06989918
- Testing
- MHB018A
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Thyroid Eye Disease, TED, Graves Orbitopathy
Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).
- Trial name
- ORBIT (NCT07753603)
- Testing
- linsitinib
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Sling Therapeutics, Inc.
Basedow Disease
Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment
Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).
- Trial name
- HZN-IIT (NCT07117981)
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Graves' Orbitopathy
A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study
Graves' orbitopathy (GO) is the most common extra-thyroidal manifestation of Graves' disease (GD). Based on its clinical signs and symptoms, GO is graded as mild, moderate-to-severe, or severe, and active or inactive, the latter…
- Trial name
- STAGO-2 (NCT05049603)
- Testing
- Atorvastatin 20mg
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- University of Pisa
Thyroid Eye Disease
A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease
The main goal of this study is to learn how teprotumumab will be processed in the body (Pharmacokinetics) subcutaneously and whether it is safe and tolerable after administration into adult patients with thyroid eye disease.
- Trial name
- NCT06389578
- Testing
- Teprotumumab
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Amgen
Thyroid Eye Disease
The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)
This randomized clinical trial is designed to evaluate the effect of selected antioxidant vitamins and minerals supplement named as ASTED: 1. β- Carotene (30 mg) 2. Vit C (100 mg) 3. Vit E (Alpha-Tocopherol Acetate): 60-200 IU 4.
- Trial name
- NCT02393183
- Testing
- ASTED, Selenium
- Where
- Iran
- Sponsor
- Iran University of Medical Sciences
Graves' Orbitopathy, Graves' Disease
Microbiota and Immune SignatureS of Graves' Disease and Orbitopathy
Graves' disease (GD) is the commonest cause of hyperthyroidism, characterised by anti-thyrotropin receptor autoantibodies (TRAb) persistently stimulating the thyroid gland.
- Conditions
- Graves' Orbitopathy, Graves' Disease, Graves' Ophthalmopathy, Basedow Disease
- Trial name
- MISS:GO (NCT07870161)
- Testing
- Aspiration 0
- Where
- Italy
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).
- Trial name
- THRIVE-2 (NCT06021054)
- Testing
- Veligrotug
- Where
- 57 sites in United States, Australia and 7 more
- Volunteers
- 188 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease
Development of an AI Solution to Evaluate Clinical Activity of TAO Using Periocular Images Taken by Smartphones in Patients With Thyroid Dysfunction
This study was conducted to develop an AI solution to evaluate clinical activity score (CAS) of thyroid associated orbitopathy (TAO) using periocular selfie images taken by smartphones in patients with thyroid dysfunction.
- Trial name
- NCT05731154
- Testing
- taking periorbital selfie images using smartphones
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Bundang Hospital
Thyroid Eye Disease, Graves' Orbitopathy
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease
This is an expanded access protocol intended to provide access to teprotumumab for the treatment of up to 60 patients in the United States with active moderate to severe thyroid eye disease where there is no comparable or…
- Trial name
- EAP (NCT04040894)
- Testing
- Teprotumumab
- Where
- 8 sites in United States
- Sponsor
- Amgen
Graves Orbitopathy
Immunological Follow-up of Patients With Basedow's Orbitopathy
Graves' disease is characterized by the combination of anti-TSH receptor antibodies (Thyroid-Stimulating Hormone or thyroidotropic hormone), specific to this disease, with inconsistent symptoms such as hyperthyroidism…
- Trial name
- SIPO (NCT04610723)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Montpellier
Graves Ophthalmopathy
Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease
Thyroid eye disease is an autoimmune disorder affecting approximately 50% of individuals with autoimmune thyroid diseases resulting in enlargement of ocular muscles and may lead to congestion of the eyelids and ocular surface…
- Trial name
- CRISEPTED (NCT02339142)
- Testing
- External beam radiotherapy, intravenous corticosteroids (methylprednisolone)
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Thyroid Associated Ophthalmopathy
Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial
For patients with active moderate-to-severe thyroid associated ophthalmopathy (TAO), the Intravenous Glucocorticoids (GCs) is the recommended therapy. However, the efficacy of GCs is not satisfied.
- Trial name
- NCT03107078
- Testing
- Glucocorticoids
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Jie Shen
Thyroid Eye Disease
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with…
- Trial name
- UplighTED (NCT06307613)
- Testing
- Efgartigimod PH20 SC
- Where
- 77 sites in United States, Australia and 14 more
- Volunteers
- 102 people
- Sponsor
- argenx
Graves Ophthalmopathy
Bimatoprost as a Treatment for Graves' Orbitopathy
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
- Trial name
- NCT03708627
- Testing
- Bimatoprost Ophthalmic
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
Thyroid-associated Ophthalmopathy
Trial of Rituximab for Graves' Ophthalmopathy
This study is being done to investigate the effects (good and bad) of Rituximab for the treatment of an autoimmune eye disease called Graves' ophthalmopathy. This disease has proven to be difficult to treat.
- Trial name
- NCT00595335
- Testing
- Rituximab, Saline, Methylprednisolone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rebecca Bahn
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain.
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
- Trial name
- TOFA-GO (NCT07547930)
- Testing
- Tofacitinib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Graves Ophthalmopathy, Graves Disease
Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50 mg/d), administered for 12 weeks, on patients with mild Thyroid-Associated Ophthalmopathy (TAO).
- Conditions
- Graves Ophthalmopathy, Graves Disease, Thyroid-associated Ophthalmopathy, Thyroid Diseases
- Trial name
- NCT02203682
- Testing
- Doxycycline hyclate
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Graves Disease, Graves Ophthalmopathy
Impact of Intravenous Methylprednisolone Treatment on Blood Pressure
Hypertension is common side effect of Cushing Syndrome (CS): in patients with endogenous CS and those treated with glucocorticosteroids (GCs). The impact of the intravenous GCs therapy on blood pressure (BP) remains unclear.
- Conditions
- Graves Disease, Graves Ophthalmopathy, Hypertension, Blood Pressure
- Trial name
- NCT03590080
- Testing
- Methylprednisolone
- Volunteers
- 32 people
- Sponsor
- Medical University of Warsaw